Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from Z. Kahan and co-researchers advance knowledge in breast cancer
February 12th, 2009
According to recent research from Vienna, Austria, "Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC60 providing little benefit over standard chemotherapy and FEC100 associated with toxicity." "We investigated the feasibility of two intermediate dose-dense FEC regimens. Patients were randomised to six cycles of FEC75 or FEC90, with all three drugs given on day 1 of each 14-day cycle. Patients also received...
Source: Women's Health Weekly (2009-02-12)
|
